Rice Hall James & Associates LLC decreased its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 3.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 235,234 shares of the company’s stock after selling 9,561 shares during the quarter. Rice Hall James & Associates LLC owned about 0.65% of Aerie Pharmaceuticals worth $11,432,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. increased its stake in shares of Aerie Pharmaceuticals by 11.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after acquiring an additional 275 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after acquiring an additional 3,579 shares during the last quarter. BlueCrest Capital Management Ltd acquired a new position in shares of Aerie Pharmaceuticals during the 1st quarter valued at about $202,000. Amalgamated Bank acquired a new position in shares of Aerie Pharmaceuticals during the 2nd quarter valued at about $204,000. Finally, Palisade Capital Management LLC NJ acquired a new position in shares of Aerie Pharmaceuticals during the 2nd quarter valued at about $212,000. 94.71% of the stock is owned by institutional investors.

A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Mizuho reaffirmed a “buy” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 25th. Canaccord Genuity set a $65.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 16th. Finally, Guggenheim assumed coverage on shares of Aerie Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $80.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $69.71.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.02.

WARNING: “Rice Hall James & Associates LLC Has $11.43 Million Position in Aerie Pharmaceuticals, Inc. (AERI)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/02/rice-hall-james-associates-llc-has-11-43-million-position-in-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.